Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT04053231
Starting soon Observational

Hepatocarcinoma Recurrence on the Liver Study - Part2

NCT04053231 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Milano Bicocca
Phase
Observational
Started
2019-09
Last updated
2019-08-12

Condition(s) studied

Liver CancerSurgeryRecurrence TumorCirrhosis

Investigational drug(s) / intervention(s)

liver resection

liver resection: all type of liver surgical procedures

Study summary

Rationale for the trial. To evaluate the impact of surgery on hepatocarcinoma recurrence. Thus, to evaluate the impact of different clinical, radiological, histopathological variables on recurrence after surgical treatment. The nature of this study will allow to observe, over time, the distribution of the considered collection variables, allowing a strictly observational monitoring of possible associations able to suggest models or interpretations, which can then be the basis for the construction of prospective and randomized studies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * No age limit. * Hepatocarcinoma diagnosis confirmed at histological specimen * Every single patients with first HCC diagnosis or with a recurrence/persistence disease evaluated and treated with surgery at the participating center. * the assessment for patient enrollment must have been performed starting from 02/02/2019. Exclusion Criteria: * Surgery as a downstaging therapy for transplant * Patients treated with surgery in case of not-curative intent (palliation, best supportive care, etc). * Histopathological specimen of combined liver primary neoplasms (e.g. "hepatocholangiocarcinoma''). * Patients with other tumors in the previous past.

Primary outcome measure(s)

  • Disease-free-Survival — 15 years of follow-up
    Disease Free Survival: the time between surgery and event of recurrence or death measured in months. If no event, patients will be censored at the last available follow-up date.
  • Overall Survival — 15 years of follow-up
    The time from surgery to death measured in months. If no event, patients will be censored at the last available follow-up.

Trial sites (19)

FacilityCityRegionStatus
Chirurgia Rubino - Policlinico di Bari Bari Italy
Ospedale Maggiore- AUSL Bologna Italy
Chirurgia Generale Bolzano Bolzano Italy
Fondazione Poliambulanza - Istituto Ospedaliero Brescia Italy
Spedali Civili Brescia Italy
Chirurgia Generale Ospedale Pierantoni - Morgagni Forlì Italy
Ospedale A. Manzoni - ASST Lecco Lecco Italy
ASST-Mantova Mantua Italy
Asst-Fbf-Sacco Polo Universitario H. Sacco Chirurgia 2 Milan Italy
IRCCS Osp. San Raffaele, Divisione Chirurgia Generale Epatobiliare Milan Italy
Policlinico di Monza Monza Italy
UOS Chirurgia Oncologica ad inidirzzo epato-bilio-pancreatico Parma Italy
Fondazione IRCCS Policlinico San Matteo Pavia Italy
Fondazione Policlinico Universitario A. Gemelli, IRCCS Rome Italy
Irccs Istituto Nazionale Tumori Regina Elena Rome Italy
Humanitas Research Hospital Rozzano Italy
Ospedale San Paolo Savona Italy
Chirurgia 4 Ospedale Ca'Foncello Treviso Italy
Chirurgia Epatobiliare Università degli studi di Verona Verona Italy

More University of Milano Bicocca trials in Italy

FDG-PET in the Diagnosis of Autoimmune Encephalitis Recruiting
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 Recruiting
Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network Recruiting
Art of Memory for Cognitive Enhancement in the Monza Brain Health Service Active, not recruiting
Non-invasive Vibratory Stimulation of the Knee Muscles for the Improvement of the Somatosensory Input and Motor Performance Recruiting

Other trials for the same condition

Surgical TReatment of Women With Deep ENDometriosis Recruiting
Latissimus Dorsi Flap Reconstructions: Retrospective Study Recruiting
ESP Block Versus Wound Infiltration for Laminectomy Recruiting
Transanal Transection and Single-stapled Anastomosis (TTSS) in Rectal Cancer Patients Recruiting
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04053231 on ClinicalTrials.gov ↗ ← All trials in Italy